WallStSmart

Brookfield Business Corp (BBUC)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Brookfield Business Corp generates 125% more annual revenue ($27.46B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs -0.1%. VRTX earns a higher WallStSmart Score of 66/100 (B-).

BBUC

Hold

43

out of 100

Grade: D

Growth: 6.0Profit: 5.0Value: 6.7Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BBUCUndervalued (+88.8%)

Margin of Safety

+88.8%

Fair Value

$324.96

Current Price

$30.85

$294.11 discount

UndervaluedFair: $324.96Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBUC1 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

BBUC3 concerns · Avg: 2.0/10
Return on EquityProfitability
2.4%3/10

ROE of 2.4% — below average capital efficiency

Revenue GrowthGrowth
-4.5%2/10

Revenue declined 4.5%

Profit MarginProfitability
-0.1%1/10

Currently unprofitable

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BBUC

The strongest argument for BBUC centers on Price/Book.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : BBUC

The primary concerns for BBUC are Return on Equity, Revenue Growth, Profit Margin.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BBUC profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.

BBUC carries more volatility with a beta of 1.38 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 43/100), backed by strong 35.5% margins. BBUC offers better value entry with a 88.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Business Corp

INDUSTRIALS · CONGLOMERATES · USA

Brookfield Business Corporation focuses on healthcare, construction and wastewater services in the United States, Europe, Australia, the United Kingdom, Canada and Brazil. The company is headquartered in New York, New York.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?